IMMUTEP Ltd

IMMP

Explore Our Financial Data > Companies > IMMUTEP Ltd

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	IMMP
CIK	0001506184
SIC	2834
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Pharmaceutical Preparations

Contact

Address	LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE, 264 GEORGE STREET, SYDNEY,, C3, NSW 2000
Website	immutep.com
Phone	612 8315 7003
CEO	Marc Voigt
Employees	N/A

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$2.57 million
Pre-Tax Income	$-28.52 million
Net Income	$-28.52 million
Net Income to Common	$-28.52 million
EPS	$-0.02

View All

Balance Sheet

Cash	$108.03 million
Assets	$134.59 million
Liabilities	$7.41 million
Common Equity	$126.54 million
Liabilities & Equity	$133.95 million

View All

Cash Flow Statement

Net Income	$-28.52 million
Cash From Operating Activities	$-23.25 million
Cash From Investing Activities	$-14.03 million
Cash From Financing Activities	$63.55 million
Change in Cash	$-15.00 million

View All

Calculations

NOPAT	$-21.77 million
EBITDA	$-31.11 million
Price to Earnings	N/A
Price to Book	$1.95
ROE	-26.23%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

High Growth Tech Stocks in Australia July 2025

As Australian shares track U.S. trends with the ASX 200 futures pointing to a modest gain, buoyed by Wall Street's record highs and strong performances in tech-heavy indices like the Nasdaq, there's a growing interest in high-growth tech stocks within Australia. In this dynamic market environment, identifying promising stocks often involves looking for companies that are not only innovative but also well-positioned to benefit from technological advancements and investor enthusiasm as...

Article Link

Exploring High Growth Tech Stocks In Australia July 2025

As the Australian market navigates a complex landscape marked by fluctuating iron ore prices and economic indicators pointing to persistent deflation in China, investors are keenly observing the tech sector for potential high-growth opportunities. In this environment, identifying promising tech stocks involves assessing their ability to innovate and adapt amidst broader market shifts, such as those influenced by commodity trends and central bank decisions.

Article Link

Exploring Three High Growth Tech Stocks In Australia

The Australian market has recently reached an all-time high, driven by a strong rally in the mining sector and expectations of potential rate cuts by the Reserve Bank of Australia, although the tech sector faced some challenges due to external factors. In this environment, identifying high growth tech stocks requires careful consideration of their resilience and potential to thrive despite broader market fluctuations.

Article Link

Immutep (IMMP) Announces Positive Initial Efficacy Data and Continued Favourable Safety Data

Immutep Limited (NASDAQ:IMMP) is one of the 7 Best ASX Stocks to Buy Now. On June 23, Immutep Limited (NASDAQ:IMMP) announced positive initial efficacy data and continued favourable safety data from the placebo-controlled, double-blind first-in-human Phase I study evaluating IMP761. This is the first-in-class LAG-3 agonist antibody for autoimmune diseases. The company stated that through the highest […]

Article Link

ASX Penny Stocks Spotlight: Arafura Rare Earths And Two More To Consider

The Australian market has been experiencing a mixed performance, with the ASX200 trading flat and sectors like Health Care and Financials showing strength, while IT, Real Estate, and Industrials faced sell-offs. In such a fluctuating landscape, investors often seek opportunities in smaller or newer companies that might offer unexpected value. Penny stocks—despite their somewhat outdated name—represent this niche, where solid financial foundations can lead to significant returns. This article...

Article Link